Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRB2-associated binding protein 4 (GAB4) is a member of the GAB family of adaptor or docking proteins, which includes GAB1, GAB2, and GAB3. GAB4 is predicted to enable transmembrane receptor protein tyrosine kinase adaptor activity, functioning in intracellular signaling pathways related to receptor tyrosine kinases. However, while GAB1, GAB2, and GAB3 are well characterized—with GAB2, in particular, known to play important roles in leukemogenesis, cancer biology, and multiple signaling pathways—GAB4 remains poorly described in the published literature. There is no direct evidence that GAB4 serves as a validated therapeutic target, has known endogenous or drug ligands, or plays a direct role in human disease[3][4][5]. Most available information on GAB4 is inferred from its membership in the GAB protein family and predicted bioinformatic functions, rather than from experimental characterization or therapeutic research. Clarification: - The provided target, GRB2-associated binding protein 4 (GAB4), is not currently recognized as a validated or well-characterized therapeutic target. Most functional and disease associations are based on predictions or homology to other family members such as GAB2, which *is* therapeutically relevant and well-studied in cancer and signal transduction[1][2]. - There are no known drugs, mechanisms of action, or biomarker uses for GAB4 itself. - The target entry is likely conflated or confused with GAB2, which has extensive literature, whereas GAB4 has only sparse, predicted data. - No safety or efficacy data is available because GAB4 is not used as a therapeutic target. Summary: GAB4 is an adaptor/docking protein of the GAB family, predicted to serve as a signaling scaffold for receptor tyrosine kinases, but it is not a validated therapeutic target, and much of its function, disease association, and druggability remains to be determined[3][4][5]. The current entry may reflect a case of mistaken identity with the functionally established GAB2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRB2-associated binding protein 4 (GAB4).